NCT06189274

Brief Summary

The purpose of the study is to evaluate cochlear implant speech outcomes and subjective benefit for cochlear implant recipients with single-sided deafness using patient-specific, anatomy-based array selection versus standard of care with a fixed array size for all patients. Subjects will prospectively be assigned to receive an Anatomy-Based Electrode (FLEX26, FLEX28, or FLEXSOFT) or the Standard of Care Electrode array (FLEX28). Speech performance and subjective benefit will be evaluated between these two groups.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
10

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Apr 2024

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 18, 2023

Completed
16 days until next milestone

First Posted

Study publicly available on registry

January 3, 2024

Completed
3 months until next milestone

Study Start

First participant enrolled

April 1, 2024

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

January 3, 2024

Status Verified

December 1, 2023

Enrollment Period

1.5 years

First QC Date

December 18, 2023

Last Update Submit

December 18, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Speech perception in spatially separated noise

    Change in percent correct on the AzBio sentences in noise, with speech presented to the front and noise to the better hearing ear

    6 months post activation

Secondary Outcomes (4)

  • Speech perception in noise

    6 months post activation

  • Speech perception in quiet

    6 months post activation

  • Speech Spatial and Qualities of Hearing Scale (SSQ)

    6 months post activation

  • Datalogging

    6 months post activation

Study Arms (2)

Anatomy-Based Electrode Selection

EXPERIMENTAL

For individuals in the anatomy-based electrode (ABE) group, magnetic resolution imaging (MRI) or computed tomography (CT) scans will be evaluated by MED-EL Canada employees. Based on these results, an appropriate electrode array will be selected.

Other: Anatomy-Based Electrode Array Selection

Standard of Care Electrode Selection

ACTIVE COMPARATOR

The comparison in this study will be to current standard of care, which is to select a single electrode length for most patients, in this case the FLEX28 electrode, which is 28 mm long.

Other: Standard of Care Electrode Array Selection

Interventions

Use of pre-operative imaging to select the appropriate length electrode vs standard of care

Also known as: OTOPLAN
Anatomy-Based Electrode Selection

Use of standard of care electrode which is the FLEX 28 electrode

Standard of Care Electrode Selection

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years of age or older at the time of implantation
  • Unilateral severe to profound sensorineural hearing loss, as defined by a pure-tone average (500, 1000, 2000, and 4000 Hz) of 70 dB HL or greater
  • Normal hearing mild hearing loss in the non-implanted ear, as defined by a pure-tone average (500, 1000, 2000, and 4000 Hz) of 40 dB or less
  • Deemed an appropriate candidate by the investigator
  • Fluent in English

You may not qualify if:

  • Duration of profound hearing loss of 10 years or more
  • Sudden onset of hearing loss within six months of implantation
  • Evidence of non-functional cochlear nerve using appropriate imaging modality to be determined by the investigator
  • Other retrocochlear hearing loss
  • Evidence of severe cochlear malformation (i.e., common cavity or ossification)
  • External or middle ear infection
  • Suspected developmental or cognitive concern
  • Other medical contraindication for surgery or anesthesia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Central Study Contacts

David P Morris, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 18, 2023

First Posted

January 3, 2024

Study Start

April 1, 2024

Primary Completion

October 1, 2025

Study Completion

December 1, 2025

Last Updated

January 3, 2024

Record last verified: 2023-12

Data Sharing

IPD Sharing
Will not share